No Detail Found!

Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus

Author(s)
Museera Zahid Medicare Cardiac and General Hospital, Sohail University,Karachi,Pakistan
Samia Perwaiz Khan Department of Pharmacology, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan
Sana Ershad Department of Pharmacology, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan
Saafi Izhar Department of Radiology, Medicare Cardiac and General Hospital, Jinnah Medical and Dental College, Sohail University,Karachi,Pakistan
Rizwana Warraich Department of Molecular Biology, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan
Ali Asghar Department of Endocrinology, Medicare Cardiac and General Hospital, Jinnah Medical and Dental College, Sohail University, Karachi, Pakistan.
Abstract
Objective: To determine the prevalence of non-alcoholic fatty liver disease, and the effect of oral hypoglycaemic drugs and lifestyle modicfiations in reducing fatty liver changes and liver enzymes in these patients. Method: The comparative, observational study was conducted at the Department of Pharmacology, Sohail University, Karachi, from October 2022 to October 2023, and comprised patients of either gender having elevated liver enzymes and ultrasound nfiding of fatty liver changes along with raised glycated haemoglobin, transaminases, total cholesterol and triglycerides. The participants were prescribed oral hypoglycaemic agents by endocrinologists. Those given empaglifazolin + metformin were in group A, empaglifazolin + linglaptin in group B, sitaglaptin + metformin in group C, metformin alone in group D and sitaglaptin alone in group E. Lifestyle modicfiations were advised in all the treatment groups, while control group F was only advised lifestyle modicfiations. The intervention lasted 3 months. Investigations included B-mode ultrasound liver, liver enzymes and glycated haemoglobin, which were done at baseline and after the intervention. Data was analysed using SPSS 25. Result: Of 200 patients, 40 were males and 160 were females in ratio of 1:4. The overall mean age was 48±16 years. There were 154(77%) patients who had non-alcoholic fatty liver disease with type 2 diabetes mellitus, while 46(23%) had only fatty liver changes. There were 50(25%) patients in group A, 30(15%) in group B, 30(15%) in group C, 40(20%) in group D, 10(5%) in group E and 40(20%) in group F. Post-intervention improvement was noted in 48(24%) patients, with 20(41.7%) of them being in group A. Conclusion:The prevalence of non-alcoholic fatty liver disease with type 2 diabetes was high. Combination of empaglioflzin + metformin along with lifestyle modicfiations was highly effective in reducing fatty changes and the level of liver enzymes.
Publication Details
Page(s) 1654-1658
Published Journal: Journal of Pakistan Medical Association, Volume: 74, Issue: 9, Year: 2024

Request the full text from PASTIC

Keywords
Type 2 diabetes mellitus, metformin, AST, Non-alcoholic fatty liver diseases, SGLT2- inhibitor, ALT.
0

Citations

0

Downloads

69

Views